1. Home
  2. TRST vs CGEM Comparison

TRST vs CGEM Comparison

Compare TRST & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TrustCo Bank Corp NY

TRST

TrustCo Bank Corp NY

HOLD

Current Price

$46.17

Market Cap

782.5M

Sector

Finance

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$14.95

Market Cap

873.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRST
CGEM
Founded
1902
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
782.5M
873.4M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
TRST
CGEM
Price
$46.17
$14.95
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$30.11
AVG Volume (30 Days)
96.4K
732.3K
Earning Date
04-21-2026
05-07-2026
Dividend Yield
3.26%
N/A
EPS Growth
26.46
N/A
EPS
3.25
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.20
P/E Ratio
$14.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$28.10
$5.68
52 Week High
$48.45
$16.74

Technical Indicators

Market Signals
Indicator
TRST
CGEM
Relative Strength Index (RSI) 61.31 56.96
Support Level $41.96 $11.43
Resistance Level $46.89 $15.66
Average True Range (ATR) 0.91 0.89
MACD 0.30 0.04
Stochastic Oscillator 77.47 75.25

Price Performance

Historical Comparison
TRST
CGEM

About TRST TrustCo Bank Corp NY

Trustco Bank Corp N Y is a savings and loan holding company. The core part of a business consists of accepting deposits and making loans and investments. It offers a range of both personal and business banking services. The company's product includes savings accounts; retirement accounts; money market account; mortgages; building loans; auto loans and others. The company based on only one business segment, that of community banking. TrustCo lends in the geographic territory of its branch locations in New York, Florida, Massachusetts, New Jersey, and Vermont.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: